DDrare: Database of Drug Development for Rare Diseases

Vt30 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
278	Huge lymphatic malformation with cervicofacial lesion	1
279	Huge venous malformation with cervical, oral and pharyngeal diffuse lesion	1

278. Huge lymphatic malformation with cervicofacial lesion [ 19 clinical trials, 23 drugs, (DrugBank: 7 drugs), 5 drug target genes, 62 drug target pathways]

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 19 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04409145 (ClinicalTrials.gov)	October 1, 2020	11/5/2020	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation	Drug: VT30	Venthera, Inc.	NULL	Recruiting	18 Years	60 Years	All	51	Phase 1;Phase 2	United States

279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion [ 12 clinical trials, 23 drugs, (DrugBank: 9 drugs), 3 drug target genes, 103 drug target pathways]

Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 12 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04409145 (ClinicalTrials.gov)	October 1, 2020	11/5/2020	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation	Drug: VT30	Venthera, Inc.	NULL	Recruiting	18 Years	60 Years	All	51	Phase 1;Phase 2	United States